Influence of intravenous immunoglobulin therapy on serum levels of anti-ß4 antibodies in ocular cicatricial pemphigoid: A correlation with disease activity

Reference

• Mohimen A, Neumann R, Foster CS, Ahmed AR. De-tection and partial characterization of ocular cicatricial pemphigoid antigens on COLO and SCaBER tumor cell lines. Curr Eye Res. 1993;12:741–752.
   PubMed Web of Science ®Google Scholar
• Ahmed AR, Kurgis BS, Rogers RS, et al. Cicatricial pemphigoid. J Am Acad Dermatol. 1991;24:987–1000.
   PubMed Web of Science ®Google Scholar
• Foster CS: Cicatricial pemphigoid. Tr Am Ophthalmol Soc. 1986;84:527–663.
   PubMedGoogle Scholar
• Neumann R, Tauber J, Foster CS. Remission and recur-rence after withdrawal of therapy for ocular cicatricial pemphigoid. Ophthalmology. 1991;98:858–862.
   Google Scholar
• Foster CS, Neumann R, Tauber J. Long-term results of systemic chemotherapy for ocular cicatricial pemphig-oid. Doc Ophthalmol. 1992;82:223–9.
   Google Scholar
• Foster CS, Ahmed AR. Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid. Ophthalmol-ogy. 1999;106:2136–2143.
   PubMed Web of Science ®Google Scholar
• Power WJ, Neves RA, Rodriguez A, et al. Increasing the diagnostic yield of conjunctival biopsy in patients with suspected ocular cicatricial pemphigoid. Ophthal-mology. 1995;102:1158–1163.
   PubMed Web of Science ®Google Scholar
• Chan LS, Yancey KB, Hammerberg C, et al. Immune-mediated subepithelial blistering diseases of mucous membranes. Pure ocular cicatricial pemphigoid is a unique clinical and immunopathological entity distinct from bullous pemphigoid and other subsets identified by an-tigenic specificity of autoantibodies. Arch Dermatol. 1993; 129:448–55.
   Google Scholar
• Bhol K, Mohimen A, Neumann R, et al. Differences in the anti-basement membrane zone antibodies in ocular and pseudo-ocular cicatricial pemphigoid. Curr Eye Res. 1996;15:521–32.
   PubMed Web of Science ®Google Scholar
• Lazarova Z, Hsu R, Yee C, Yancey KB. Antiepiligrin cicatricial pemphigoid represents an autoimmune response to subunits present in laminin 5 (alpha3beta3gamma2). Br J Dermatol. 1998;139:791–7.
   PubMedGoogle Scholar
• Ahmed AR, Khan KN, Wells P, et al. Preliminary sero-logical studies comparing immunofluorescence assay with radioimmunoassay. Curr Eye Res. 1989; 8:1011–1019.
   Web of Science ®Google Scholar
• Ghohestani RF, Nicolas JF, Rousselle P, Claudy AL. Identification of a 168-kDa mucosal antigen in a subset of patients with cicatricial pemphigoid. J Invest Dermatol. 1996;107:136–9.
   Google Scholar
• Fujimoto W, Toi Y, Okazaki F, et al. Anti-epiligrin cica-tricial pemphigoid with IgG autoantibodies to the beta and gamma subunits of laminin 5. J Am Acad Dermatol. 1999;40:637–9.
   Google Scholar
• Kanitakis J, Zambruno G, Vassileva S, et al. Alpha-6 (CD 49f) integrin expression in genetic and acquired bullous skin diseases. A comparison of its distribution with bullous pemphigoid antigen. J Cutan Pathol. 1992; 19:376–84.
   Google Scholar
• Shimizu H, Masunaga T, Ishiko A, et al. Autoantibod-ies from patients with cicatricial pemphigoid target dif-ferent sites in epidermal basement membrane. J Invest Dermatol. 1995;104:370–3.
   PubMed Web of Science ®Google Scholar
• Tyagi S, Bhol K, Natarajan K, et al. Ocular cicatricial pemphigoid antigen: partial sequence and biochemical characterization. Proc Natl Acad Sci USA. 1996; 93: 14714–14719.
   PubMed Web of Science ®Google Scholar
• Chan RY, Bhol K, Tesavibul N, et al. The role of anti-body to human beta4 integrin in conjunctival basement membrane separation: possible in vitro model for ocu-lar cicatricial pemphigoid. Invest Ophthalmol Vis Sci. 1999;40:2283–90.
   PubMed Web of Science ®Google Scholar
• Mohimen A, Ahmed AR. Comparison of an indirect immunofluorescence assay and a modified sensitive immunoblot assay for the study of the autoantibody in pemphigus vulgaris. Arch Dermatol Res. 1995;287:202–8.
   Google Scholar
• Van Waes C, Kozarsky KF, Warren AB, et al. The A9 antigen associated with aggressive human squamous carcinoma is structurally and functionally similar to the newly defined integrin alpha 6 beta 4. Cancer Res. 1991; 51:2395–402.
   PubMed Web of Science ®Google Scholar
• Kristiansen M, Aggerbeck H, and Heron I. Improved ELISA for determination of anti-diphtheria and or anti-tetanus antitoxin antibodies in sera. APMIS. 1997; 105:843–853.
   Google Scholar
• Chan LS, Lapiere JC, Chen M, et al. Bullous systemic lupus erythematosus with autoantibodies recognizing multiple skin basement membrane components, bullous pemphigoid antigen 1, laminin-5, laminin-6, and type VII collagen. Arch Dermatol. 1999;135:569–573.
   PubMedGoogle Scholar
• Venning V, Frith PA, Bron AJ, et al. Mucosal involve-ment in bullous and cicatricial pemphigoid. A clinical and immunopathological study. Br J Dermatol. 1988; 118:7–15.
   PubMed Web of Science ®Google Scholar
• Smoller BR, Woodley DT. Differences in direct immu-nofluorescence staining patterns in epidermolysis bullosa acquisita and bullous pemphigoid. J Am Acad Dermatol. 1992;27:Pt 1,674–678.
   Google Scholar
• Adachi A, Tani M, Matsubayashi S, et al. Immuno-electronmicroscopic differentiation of linear IgA bullous dermatosis of adults with coexistence of IgA and IgG deposition from bullous pemphigoid. J Am Acad Dermatol. 1992;27:394–399.
   Google Scholar
• Bosch X, Forns X, Font J, et al. Neutrophil anticytoplas-mic antibodies in a patient with Wegener's granuloma-tosis: therapeutic implications of its detection and rela-tion to clinical activity. Med Clin (Barc). 1991;97:780–2.
   Google Scholar
• Hohlfeld R, Toyka KV, Besinger UA, et al. Myasthenia gravis: reactivation of clinical disease and of autoimmune factors after discontinuation of long-term azathioprine. Ann Neurol. 1985; 17:238–42.
   PubMed Web of Science ®Google Scholar
• Perez Vazquez ME, Villa AR, Drenkard C, et al. Influence of disease duration, continued followup and further antiphospholipid testing on the frequency and classifi-cation category of antiphospholipid syndrome in a co-hort of patients with systemic lupus erythematosus. J Rheumatol. 1993;20:437–42.
   Google Scholar
• Corzillius M, Schroeder JO, Euler HH. Comparison of three indices for the evaluation of disease activity in systemic lupus erythematosus. Z Rheumatol. 1991;50: 371–377.
   Google Scholar
• Khan IU, Bhol KC, Ahmed AR. Linear IgA bullous dermatosis in a patient with chronic renal failure: Re-sponse to intravenous immunoglobulin therapy. J Am Acad Dermatol. 1999;40:485–488.
   Google Scholar
• Dammacco F, Iodice G, Campobasso N. Treatment of adult patients with idiopathic thrombocytopenic purpura with intravenous immunoglobulin: effects on circulating T cell subsets and PWM-induced antibody synthesis in vitro. Br J Haematol. 1986;62:125–35.
   Google Scholar
• Jongen JL, van Doom PA, van der Meché FG. High-dose intravenous immunoglobulin therapy for myasthe-nia gravis. J Neurol. 1998;245:26–31.
   Google Scholar
• ODonnell BF, Barr RM, Black AK, et al. Intravenous immunoglobulin in autoimmune chronic urticaria. Br J Dermatol. 1998;138:101–106.
   Google Scholar
• Sultan Y, Kazatchkine MD, Maisonneuve P, Nydegger UE. Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin. Lancet. 1984;2:765–768.
   PubMed Web of Science ®Google Scholar